Posted by Michael Wonder on 24 May 2017
NICE terminates appraisal of afatinib dimaleate
24 May 2017 - NICE was to assess afatinib dimaleate for treatment of patients with advanced squamous non-small-cell lung cancer after platinum-based chemotherapy.
NICE is unable to make a recommendation about the use in the NHS of afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy because no evidence submission was received from Boehringer Ingelheim.
NICE will review this decision if the company decides to make a submission.
